All episodes
IMpower 110 & Checkmate 153
ESMO 2020 & Beyond
TAX 327
Pralsetinib
BROCADE3
Alopecia
ATAC
VIALE-A (venetoclax + azacitidine for elderly/unfit AML)
New Anti-CD-19 And BCMA Options
Gemcitabine
Antiemetic & CIPN Guideline Updates
Conversation With A Breast Cancer Survivor
Neutropenic Fever 101
Early July FDA Updates
Clinical Trial Endpoints in Oncology
Lurbinectedin et al
LD Vs Ld
ASCO 2020
More NSCLC Updates (Checkmate-9La & ALTA-1L)
New Chemo - Free Immunotherapy Options For NSCLC
Selpercatinib & More!
Capmatinib & SC Daratumumab
Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin
Sacituzumab Govitecan, Tucatinib, And More!
Journal Club: Unscheduled Hydration in Patients Receiving HEC
Bevacizumab's Wild Ride For Metastatic Breast Cancer
Caravaggio
Bleomycin
Recent Landmarks (CLEOPATRA, Keynote189)
*Covid19 And Chemo*
Viz-Aflibercept Pricing: A Case Study
Pre - HOPA News Dunp
CYP2D6 & Tamoxifen Updates
CAR - NK
NK - 1 Antagonist Drug Interactions
Tazemetostat
Bendamustine
Avapritinib
Safety Signals & 6 - MP Hepatotoxicity
Trastuzumab Deruxtecan
Enfortumab-vedotin (& Asciminib)
Arsenic Sauce
ASH '19 Updates
Dose Dense AC
Cornucopia Of OncoPharm Updates
Zanubrutinib
Immunotherapy Interactions
Data Dive Into NK-1 Antagonists & Carboplatin
Carboplatin
ADAM VTE & Ibrutinib CV Toxicity
To Rechallenge, Or Not To Rechallenge
CASPIAN
ESMO 2019
Danorubicin 90 mg/m2 (AML induction)
New FDA approved indications for lenvatinib, pembro, and apalutamide
Curious Case Of Ibrutinib On Netflix
OncoPharm M & M Extreme Toxicity & Pharmacogenetics
Irinotecan
Entrectinib & Fedratinib
E1912: Ibrutinib/rituximab vs. FCR in CLL
ASCO VTE Guidelines (& more!)
Darolutamide
AC - - > T (q week)
Selinexor
Pain Management In Cancer
Tamoxifen
Ask OncoPharm: Advice for PGY2 Oncology Pharmacy Residents
Pembrolizumab Nets 2 More Approvals
Polatuzumab-vedotin
ASCO '19
Alpelisib
AC - - > T (q 3 week)
AC (NSABP B-15)
May Approvals, More Questions
Imatinib
Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML
Lenvatinib vs. Sorafenib (HCC)
Erdafitinib
HOPA '19 Reflections
OncoPharm M & M - Drug Interaction
Etoposide
Updates: Venetoclax use in multiple myeloma, atezolizumab in small cell lung cancer
Metastatic Pancreatic CAncer
S.C. Monoclonal Antibodies
Lessons Learned (from the last week)
Axitinib's Big Weekend
IRIS
Cannabidiol (CBD) & Potential Drug Interactions In Cancer Patients
Mucositis & Stomatitis
Olaratumab, Goodbye?
Conversation With An Osteosarcoma Survivor
New & Niche Drugs
mFOLFIRINOX
Let's Talk About Mr. Gower
FOLFOX (MOSAIC Trial)
Gilteritinib
Elderly AML & Larotrectinib
Rise (& Fall) Of ESAs
Cyclophosphamide
Lorlatinib